TM

Tapan Maniar

Chief Business Officer at Aiolos Bio | Ex-Bain Capital Life Sciences and Genentech BD

Cambridge, Massachusetts

Investor
VC

Invests in

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Education

Lists including Tapan

AP
AO
AS
AN

Based in UK

1884 people

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Work Experience

AB
Aiolos Bio

2023

  • Chief Business Officer & Co-Founder

    2023

EB
Emalex Biosciences

2022 - 2023

  • Board Observer

    2022 - 2023

RP
Rivus Pharmaceuticals

2022 - 2023

  • Board Observer

    2022 - 2023

BC
Bain Capital

2021 - 2023

  • Principal

    2021 - 2023

G
Genentech

2017 - 2021

  • Genentech Head of BD for Tech Platforms | Pharma Partnering

    2017 - 2021

    Led Genentech's BD efforts to access research technology platforms and novel modalities across therapeutic areas. Executed numerous discovery/pre-clinical stage collaborations, clinical-stage partnerships, and an M&A. Notable transactions include: Heptares (GPCR targeting), Scenic Biotech (Genetic Modifiers), X-Chem (DEL for Oncology), Skyhawk Tx (SM RNA splicing), Ribometrix (RNA modulation), Genesis Tx (ML for small molecules) and Prescient Design (ML for large molecules).

M&
McKinsey & Company

2013 - 2017

  • Engagement Manager

    2015 - 2017

  • Associate

    2013 - 2014

Rockefeller University / Howard Hughes Medical Institute

2011 - 2012

  • Postdoctoral Associate

    2011 - 2012

TR
The Rockefeller University

2004 - 2011

  • Graduate Student

    2004 - 2011

RU
Rockefeller University

2003 - 2003

  • Summer Research Assistant (SURF Program)

    2003 - 2003

BC
Bard College

2001 - 2003

  • Research Assistant (ISROP Program)

    2001 - 2003